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OBJECTIVES We sought to investigate the clinical benefit of additional stent implantation after achieving
an optimal result of balloon angioplasty (BA) in long coronary lesions (20 mm).
BACKGROUND Long coronary lesions are associated with increased early complications and late restenosis
after BA. Stenting improves the early outcome, but stent restenosis is also related to both
lesion length and stent length.
METHODS A total of 437 patients with a single native lesion 20 to 50 mm in length were included and
underwent BA, using long balloons matched to lesion length and vessel diameter (balloon/
artery ratio 1.1) to achieve a diameter stenosis (DS) 30% by on-line quantitative coronary
angiography (QCA). “Bail-out stenting” was performed for flow-limiting dissections or
50% DS. Patients in whom an optimal BA result was achieved were randomized to
additional stenting (using NIR stents) or no stenting. The primary end point was freedom
from major adverse cardiac events (MACE) at nine months, and core laboratory QCA was
performed on serial angiograms.
RESULTS Bailout stenting was necessary in 149 patients (34%) and was associated with a significantly
increased risk of peri-procedural infarction (p  0.02). Among the 288 randomized patients,
the mean lesion length was 27  9 mm, and the vessel diameter was 2.78  0.52 mm. The
procedural success rate was 90% for the 143 patients assigned to BA alone (control group),
as compared with 93% in the 145 patients assigned to additional stenting (stent group), which
resulted in a superior early minimal lumen diameter (0.54 mm, p 0.001) and led to reduced
angiographic restenosis (27% vs. 42%, p 0.022). Freedom from MACE at nine months was
77% in both groups.
CONCLUSIONS A strategy of provisional stenting for long coronary lesions led to bailout stenting in one-third
of patients, with a threefold increase in peri-procedural infarction. Additional stenting yielded
a lower angiographic restenosis rate, but no reduction in MACE at nine months. (J Am
Coll Cardiol 2002;39:393–9) © 2002 by the American College of Cardiology
Coronary lesion length is an independent risk factor for
early complications during balloon angioplasty (BA) (1,2).
Furthermore, angiographic restenosis rates of up to 58%
have been reported after BA of long lesions, and lesion
length is an independent predictor of restenosis (3,4). Long
balloons (5), and especially coronary stents, have improved
procedural success, but the long-term outcome of stents in
long lesions cannot compete with the results of the BElgian
NEtherlands STENT (BENESTENT) trial and the STent
REStenosis Study (STRESS) in focal lesions (6,7). Reste-
nosis rates of 30% to 63% have been reported for stenting of
long lesions, and stented segment length is an independent
predictor of restenosis (8–10). The optimal percutaneous
approach to long lesions remains unclear thus far.
In focal lesions, the concept of “provisional stenting” (11)
has demonstrated that a “stent-like” or “optimal” result
using BA achieves clinical and angiographic results equiva-
lent to those of stent implantation, so that stenting could be
reserved for lesions in which an optimal result cannot be
From *Erasmus University, Rotterdam, The Netherlands; †Sint Antonius Zieken-
huis, Nieuwegein, The Netherlands; ‡Ziekenhuis De Weezenlanden, Zwolle, The
Netherlands; §Hoˆpital de la Citadelle, Lie`ge, Belgium; Medisch Centrum “De
Klokkenberg”, Breda, The Netherlands; ¶UZ Virga Jesse, Hasselt, Belgium; #Centro
Cuore Columbus, Milan, Italy; **Universita¨tsklinikum Charite´, Berlin, Germany;
††CHU Sart Tilman, Lie`ge, Belgium; ‡‡Wessex Cardiology Centre, Southampton,
United Kingdom; §§Boston Scientific GmbH, Ratingen, Germany;  Cardialysis,
Rotterdam, The Netherlands; and ¶¶Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium.
All of the investigators of the Additional Value of NIR Stents for Treatment of Long
Coronary Lesions (ADVANCE) study are listed in the Appendix. This study was
supported by Boston Scientific GmbH, Ratingen, Germany.
Manuscript received July 10, 2001; revised manuscript received October 17, 2001,
accepted November 1, 2001.
Journal of the American College of Cardiology Vol. 39, No. 3, 2002
© 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(01)01760-0
achieved (12–14). The value of additional stenting after
achievement of an optimal BA result in long coronary
lesions has not been investigated; therefore, this study was
initiated.
METHODS
Study group. Patients with stable or unstable angina or
reversible ischemia related to a single, native, primary
coronary lesion 20 to 50 mm in length, in a vessel 2.5 to
4.0 mm in diameter, were eligible for inclusion. Exclusion
criteria included myocardial infarction (MI) within the five
days before enrolment, Q-wave MI with akinesia in the
target vessel territory, ejection fraction 30%, history of
stroke, gastrointestinal bleeding within six months, severe
hepatic disease, serum creatinine 130 mol/liter, contra-
indication to or intolerance of aspirin or ticlopidine, unpro-
tected left main coronary artery lesion, total occlusion
(Thrombolysis in Myocardial Infarction [TIMI] trial flow
grade 0), bifurcation lesion (side branch 2.0 mm), aorto-
ostial lesion and large intra-luminal thrombus.
Trial design. This prospective, randomized, multicenter
trial assumed a 40% incidence of the primary end point (i.e.,
cumulative major adverse cardiac events [MACE] at nine
months) in the control group (optimal BA result, random-
ized to no additional stenting) and 26% in the stent group
(optimal BA result, randomized to additional stenting). A
total of 500 patients (2  250) were required to obtain a
power of 90% with   0.05 for a two-tailed test. With an
anticipated 20% to 25% rate of bail-out stenting, 650
patients were needed to retain 500 evaluable patients.
Trial procedure and randomization. Suitable patients
gave written, informed consent before undergoing angiog-
raphy before the intervention. Ticlopidine, 250 mg twice
daily, or clopidogrel, 75 mg/day, was administered to all
patients within 12 h before the intervention and for one
month subsequently to those undergoing stent implanta-
tion. Heparin (10,000 U) and aspirin (250 mg intrave-
nously) were given according to standard protocol; aspirin,
100 mg/day, was continued indefinitely. Use of the
platelet glycoprotein IIb/IIIa receptor antagonist was at the
discretion of the investigators.
After baseline angiography had established the patients’
suitability for inclusion, the allocation service was tele-
phoned to report inclusion and provide patient identity,
lesion length, vessel diameter and diameter stenosis (DS) by
on-line quantitative coronary angiography (QCA). Target
lesion BA was then performed to achieve DS 30%
without significant dissection, using balloons of sufficient
length to cover the entire lesion with a single inflation and
a final balloon/artery ratio of 1.1. When an optimal result
had been achieved, whereby in daily practice the procedure
would be considered successfully completed, the trial ran-
domization service was again telephoned to report BA
procedural success, lesion length, vessel diameter and post-
angioplasty diameter stenosis. Then randomization took
place, either to no further therapy or to additional stenting.
When bail-out stenting had been performed, the allocation
service was also called to report this.
In patients randomized to no further therapy, the final
post-BA angiographic views were recorded for off-line
analysis at the core laboratory. In those randomized to
additional stenting, premounted NIR stents (Boston Scien-
tific Corp., Maple Grove, Minnesota) of the appropriate
length and diameter were implanted to achieve an optimal
result, using the least number of stents possible, while fully
covering the lesion (ideally a single stent) (Table 1). So-
called “spot stenting” was excluded. The NIR stents were
available in diameters from 2.5 to 4.0 mm and lengths of 9,
16, 25 and 32 mm.
Bail-out stenting. Bail-out stenting was reserved for cases
where repeated dilations with appropriately sized balloons
failed to achieve DS50% in all views by on-line QCA; for
a type C dissection (according to the National Heart, Lung
and Blood Institute classification), combined with docu-
mented ST segment changes or anginal pain; for type D, E
or F dissections; or for a reduction in TIMI flow of at least
one grade or TIMI flow grades 0 and 1. All types of stent
(preferably premounted NIR) were permitted.
Abbreviations and Acronyms
BA  balloon angioplasty
CK  creatine kinase
DS  diameter stenosis
IVUS  intravascular ultrasound
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal lumen diameter
TIMI  Thrombolysis In Myocardial Infarction
TVR  target vessel revascularization
QCA  quantitative coronary angiography
Table 1. Stent Implantation Strategy
Lesion
Length (mm)
Stent Lengths (mm)
First Choice Second Choice Third Choice
20–24 25 or 32 16  9, 16  16 or 25  9 3  9 or 2  9  16
25–30 32 or 25  9 25  9 or 16  16 16  9  9
31–40 32  9, 32  16
or 25  16
16  16  9 any combination
41–50 25  9, 32  16,
25  25 or 32  25
16  16  16, 25  16  9, 9  9 
32, 16  16  25 or 9  16  32
any combination
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End points and definitions. The primary end point was
the occurrence of MACE during nine months of follow-up,
defined previously (15) as the occurrence of cardiac death,
MI, coronary artery bypass graft surgery or repeat percuta-
neous transluminal coronary angioplasty (i.e., target vessel
revascularization [TVR]).
CARDIAC DEATH. All deaths were considered as cardiac-
related, unless unequivocally documented as noncardiac
(based, whenever possible, on an autopsy). Myocardial
infarction was defined as 1) development of new abnormal
Q waves (Minnesota Code) not present at study inclusion
(baseline); and 2) an increase of creatine kinase (CK) of
more than twice the upper limit of normal and an abnormal
level of CK-MB isoenzyme, measured routinely at screening
and 6 and 12 h after the intervention and where clinically
indicated.
TARGET VESSEL REVASCULARIZATION. The procedure of
TVR, defined as the repeat treatment of a lesion in a
previously treated vessel, was justified by recurrent symp-
toms and/or reversible ischemia in advance of repeat cath-
eterization, or diminished coronary flow reserve or fractional
flow reserve, combined with DS 50% during repeat
catheterization. Telephone notification to the allocation
center was required before repeat revascularization, for
documentation and justification.
TREATMENT SUCCESS. Core laboratory criteria for angio-
graphic success were DS 50% and TIMI flow grade 3 in
the control group and DS 30% and TIMI flow grade 3 in
the stent group. Procedural success was measured angio-
graphically and by the absence of MACE during the
hospital period. In the group randomized to additional
stenting, strategic success was defined by attainment of the
“first-choice” stent strategy (Table 1).
Ethical conduct. This study was conducted in accordance
with the Declaration of Helsinki. Patients received detailed,
written information on the trial and gave written consent
according to national requirements. No center started until
written approval of the protocol and consent procedure was
obtained from the appropriate Ethical Review Committee
and Institutional Review Board. The study complied with
Good Clinical Practice and European Standard EN 540,
governing the conduct of clinical investigations of medical
devices. Source data verification was performed.
Angiographic procedures. Coronary angiography was per-
formed in at least two views after intracoronary injection of
0.1 to 0.3 mg of nitroglycerin or 1 to 3 mg of isosorbide
dinitrate at baseline and repeated after BA and after stenting
and at follow-up angiography for the randomized patients.
Standardized procedures were followed to facilitate quanti-
tative analysis at the core laboratory (Cardialysis, Rotter-
dam, The Netherlands, using the CAAS II system [PIE
Medical, Maastricht, The Netherlands]), as extensively
described previously (4,6,9,12,15).
Follow-up. All patients visited the out-patient clinic at
one, six and nine months after the intervention; an exercise
tolerance test was also performed at six months, and in
randomized patients, follow-up angiography was carried out
on the same day or at least within the next two weeks,
according to well-described standardized procedures.
Statistical analysis. Primary end points were analyzed
according to the intention-to-treat principle. Safety analysis
was performed for all patients included. Ordinal variables
were analyzed by the Fisher exact test; continuous variables
by analysis of variance; MACE-free survival in the primary
efficacy group at nine months by the log-rank test; and
event-free survival distributions by the Kaplan-Meier
method.
RESULTS
Interim analysis. A planned interim analysis after 280
patients completed nine months of follow-up was per-
formed in September 1999. Survival free of MACE was
lower in the additional stenting group than in the control
group (81% vs. 86%, p  NS). Because the hypothesized
advantage of additional stenting over BA (a 14% reduction
in MACE) could not be substantiated with the existing trial
design, the Safety and Data Monitoring Board recom-
mended that patient recruitment be curtailed and the 437
patients included (Tables 2 and 3) be followed and analyzed,
according to the protocol.
Early results (Table 4, Fig. 1). Of the 437 patients, 149
(34%) underwent bail-out stenting because of DS 50% in
65.3%, a type D or F dissection in 63.9%, ischemia with a
type C dissection in 16.3% and/or reduced TIMI flow in
11.0%. The remaining 288 patients were randomized: 143
to no stenting and 145 to additional stenting.
Table 2. Baseline Demograpic Data on Intention-to-Treat
Patients (n  437)
Patient
Characteristics
Balloon
Angioplasty
(n  143)
Stent
Implantation
(n  145)
Bailout
Stenting
(n  149)
Male 79.0% 67.6% 71.8%
Mean age (yrs) 62.2  9.6 61.1  9.2 60.2  10.3
Previous MI 37.8% 45.5% 36.9%
Previous CABG 6.3% 3.4% 6.0%
Previous PTCA 14.7% 17.2% 9.4%
Hypertension 45.5% 40.7% 47.7%
Diabetes 15.4% 18.6% 9.4%
Insulin-dependent 4.2% 5.5% 4.7%
Hypercholesterolemia 62.2% 63.4% 64.4%
History of stroke 2.8% 2.8% 2.0%
Relevant family history 47.6% 51.7% 44.3%
Peripheral arterial disease 10.5% 9.0% 6.0%
Previous smoker 50.3% 46.9% 43.0%
Current smoker 23.8% 22.8% 22.8%
Anginal status
Unstable 30.8% 30.3% 29.5%
Stable 58.0% 64.1% 65.1%
Silent ischemia 11.2% 5.5% 5.4%
CABG coronary artery bypass graft surgery; MImyocardial infarction; PTCA
percutaneous transluminal coronary angioplasty.
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The angiographic success rate was 95.1% in the control
group and 95.9% in the additional stenting group, with
success of the first-choice stent strategy in 84%. A single
stent was used in 78%; two stents in 10%; and three or more
stents in 12%. The mean implanted stent length (by QCA
in the core laboratory) was 26.1  7.7 mm. Additional
stenting achieved a significantly greater post-procedural
minimal lumen diameter (MLD 0.54 mm, p  0.001). The
procedural success rate was 93.1% in the additional stenting
group and 89.5% in the control group (p  NS), and there
was no difference in peri-procedural MI. Cardiac enzyme
elevation was most marked in the bail-out stenting group
(21.4% had elevated CK-MB, with 7.1% more than 5 times
elevated), and significantly more patients experienced peri-
procedural MI as compared with randomized patients (p 
0.03). Among the patients with side branch occlusion, an
increase in CK occurred in 39% (2.8% of the control group,
6.2% of the additional stenting group and 6.7% of those
who had bail-out stenting). The proportions of patients
treated with glycoprotein IIb/IIIa receptor antagonists in
the additional stenting, control and bail-out groups were
7.6%, 10.5% and 10.1%, respectively.
Follow-up (Tables 4, 5 and 6, Fig. 1). The incidence of
MACE at nine months was similar between the two groups,
at 23%. There was also no difference in MLD at follow-up
(0.08 mm, p  NS), although angiographic restenosis was
higher in the control group than in the additional stenting
group (42% vs. 27%, p  0.022). The incidence of TVR
tended to be higher in the additional stenting group than in
the control group (34 vs. 28), and 20% of TVR in the stent
group was in lesions with DS50%, as compared with only
9% in the control group.
DISCUSSION
Trial design issues. The first generation of stent trials (6,7)
demonstrated the feasibility, safety and efficacy of elective
stenting as compared with BA, despite being “biased” in
favor of BA, as bail-out stenting (preventing emergency
bypass surgery or worse) was allowed in the BA strategy
(6,7). The second generation of stent trials evaluated addi-
Figure 1. Cumulative distribution of minimal lumen diameter (MLD)
before the procedure (pre), after the procedure (post) and at six-month
follow-up (fup) for the balloon angioplasty only group (n 120; solid line)
and the additional stenting group (n  124; dashed line).
Table 5. Major Adverse Cardiac Events at 31 Days in
Intention-to-Treat Patients (n  437)*
Adverse Event
Randomized
Not Randomized:
Bailout Stenting
(n  149)
Balloon
Angioplasty
(n  143)
Stent
Implantation
(n  145)
Cardiac death 0 0 0
MI 7 (4.9%) 4 (2.8%) 16 (10.7%)
Q-wave 1 (0.7%) 0 3 (2.0%)
Non–Q-wave 6 (4.2%) 4 (2.8%) 13 (8.7%)
CABG 1 (0.7%) 0 2 (1.3%)
TVR 2 (1.4%) 1 (0.7%) 0
MACE-free 133 (93.0%) 140 (96.6%) 131 (87.9%)
*If a patient required repeat angioplasty and later coronary artery bypass graft surgery
(CABG), only the worst event (CABG) was counted. Data are presented as the
number (%) of patients.
MACE  major adverse cardiac events; MI  myocardial infarction; TVR 
target vessel revascularization.
Table 3. Baseline Lesion Characteristics
Characteristics
Balloon
Angioplasty
(n  143)
Stent
Implantation
(n  145)
Bailout
Stenting
(n  149)
Calcification
(moderate to heavy)
33.3% 31.9% 29.6%
Thrombus 6.5% 5.1% 2.1%
Bifurcation lesion requiring
second wire
42% 40% 30.3%
Type A 2.1% 2.8% 4.0%
Type B1 2.1% 2.1% 1.3%
Type B2 27.3% 26.1% 22.1%
Type C 68.5% 69.0% 72.5%
RCA 42.0% 43.4% 38.5%
LAD 42.7% 37.2% 45.3%
LCx 15.4% 19.3% 16.2%
LAD  left anterior descending coronary artery; LCx  left circumflex coronary
artery; RCA  right coronary artery.
Table 4. Quantitative Coronary Angiographic Analysis
Variable
Balloon
Angioplasty
(n  120)
Stent
Implantation
(n  124)
p
Value
Lesion length (mm) 27  10 26  8 NS
Vessel size (mm) 2.76  0.53 2.80  0.53 NS
MLD (mm)
Before procedure 0.94  0.29 0.92  0.29 NS
After procedure 1.86  0.40 2.40  0.41 0.001
Follow-up 1.53  0.58 1.61  0.63 0.28
Diameter stenosis (%)
Before procedure 66  9 66  10 NS
After procedure 35  9 20  7 0.0001
Follow-up 47  16 43  18 0.07
Gain (mm) 0.92  0.39 1.47  0.47 0.001
Loss (mm) 0.33  0.48 0.79  0.58 0.001
Loss index 0.36 0.57 0.066
Restenosis rate 42% 27% 0.022
Data are presented as the mean value  SD, except where indicated otherwise.
MLD  minimal lumen diameter.
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tional stenting where an optimal BA result had been
achieved (and where bail-out stenting had been eliminated).
This “provisional stenting” strategy (11) showed that in
focal lesions, a BA-achieved DS 35%, combined with
coronary flow reserve 2.5, provided a clinical outcome
equivalent to that of additional stenting (12,14,16,17).
The Additional Value of NIR Stents for Treatment of
Long Coronary Lesions (ADVANCE) trial was the first to
evaluate provisional stenting in longer lesions. Because of
the intricacies of combining physiologic and on-line QCA
measurements in a multicenter trial, with the complexity of
long lesions, optimization of BA would be determined by
on-line QCA alone.
The surprising revelation of the interim analysis, that the
MACE rate was actually higher in the additional stenting
group, led to advice by the independent Safety and Data
Monitoring Board to the Steering Committee to terminate
inclusion, because the initial trial hypothesis could no longer
be demonstrated, which would have rendered continuing
inclusion of patients both futile and unethical. What was
surprising was the lower than expected rate of MACE of
20% in the BA-only group at that time (23% finally), as
compared with an expected rate of 40%. This may partly
reflect differences in patient selection for randomized trials,
compared with day-to-day practice, and be partly explained
by the higher than anticipated bail-out stenting rate of 34%,
which may have “removed” many patients at higher risk of
late MACE from the BA group.
Clinical implications. When embarking on this trial, three
theoretical outcomes were considered. First, the additional
value of stenting could have been demonstrated, whereby
this policy would have been recommended. Second, stenting
could have been found to be detrimental, in which case, its
restriction to bailout would have been concluded. The third
possibility, and the ultimate finding, was that additional
stenting was neither advantageous nor detrimental to the
clinical outcome, which brings about a clinical dilemma.
This study has not answered the question: should we stent
long lesions? It has, however, demonstrated that an initial
strategy of attempting optimal BA leads to bail-out stenting
in one-third of patients, with a threefold increased risk of
peri-procedural infarction, which is detrimental to the
long-term clinical outcome (18,19). Accordingly, inten-
tional stenting might be a safer and more effective initial
strategy, by avoiding the bail-out situation. In retrospect,
inclusion of an additional randomization to intentional
stenting at the time of the first allocation might have
provided data that would elucidate this possibility. How-
ever, the required sample size needed to demonstrate
superiority of this strategy would have been cost-prohibitive,
so the current design was chosen.
The majority of late events was TVR at follow-up
angiography (Fig. 2), which was artificially higher in the
stent group, as previously reported in BENESTENT-2
(20), despite our policy of prospective justification for
proposed re-interventions. Clinical follow-up, without rou-
tine angiography, would likely have led to a lower TVR rate
in the stent group and hence a better clinical outcome
(immediately before follow-up angiography, 90% of the
stent group was MACE-free vs. 85% of the BA group) (Fig.
2). It might have been useful to include such a sub-
randomization, but in this scenario, the sample size required
would have been excessive, and it was expected that clinical
justification of TVR would be followed.
Issues of stent optimization. The MLD after stenting was
rather low (2.48 mm), as compared with that in other recent
trials, such as BENESTENT-2 (2.69 mm) (20) and Mul-
ticentre Ultrasound Stenting in Coronaries (MUSIC)
(2.90 mm) (21). However, these trials included only fo-
cal lesions and a larger vessel diameter (2.78 mm in
ADVANCE) (Table 4). Actually, the late loss in the
present stent group (0.79 mm) is comparable to the loss in
these trials (0.84 mm) (6,21) and considerably less than that
observed in the Magic 5L study of long Wallstents
Table 6. Major Adverse Cardiac Events at 300 Days in
Intention-to-Treat Patients (n  437)*
Adverse Event
Randomized
Not Randomized:
Bailout Stenting
(n  149)
Balloon
Angioplasty
(n  143)
Stent
Implantation
(n  145)
Cardiac death 0 0 2 (1.3%)
MI 7 (4.9%) 4 (2.8%) 16 (10.7%)
Q-wave 1 (0.7%) 0 3 (2.0%)
Non–Q-wave 6 (4.2%) 4 (2.8%) 13 (8.7%)
CABG, all 5 (3.5%) 4 (2.8%) 4 (2.7%)
CABG, justified† 4 (2.8%) 4 (2.8%) 1 (0.7%)
TVR, all 21 (14.7%) 26 (17.9%) 17 (11.4%)
TVR, justified† 19 (13.3%) 21 (14.5%) 13 (8.7%)
MACE-free, all 110 (76.9%) 111 (76.6%) 110 (73.8%)
MACE-free, justified† 113 (79.0%) 116 (80.0%) 117 (78.5%)
*If a patient required repeat angioplasty and later coronary artery bypass graft surgery
(CABG), only the worst event (CABG) was counted. †Target vessel revascularization
(TVR) counted as “justified” only if minimal lumen diameter 1.55 mm and/or
diameter stenosis50% and a positive history of recurrent angina pectoris or objective
signs of ischemia or an abnormal invasive functional diagnostic test result. Data are
presented as the number (%) of patients.
Abbreviations as in Table 5.
Figure 2. Event-free survival during 300 days after the intervention (by the
Kaplan-Meier method). Thickest line  additional stenting group (n 
145); medium-thick line  balloon angioplasty only group (n  143);
thin line  bail-out stenting group (n  149).
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(1.20 mm) (9). Accordingly, it could be speculated that a
more aggressive strategy of post-dilation, possibly guided by
intravascular ultrasound (IVUS), could have led to improved
early and consequently late results. Guidance of stenting
with IVUS in long lesions has been shown to improve the
late outcome (22).
Lesion length as a predictor of restenosis: differences
between BA and stenting. Logistic regression analysis of
lesion length versus restenosis rate and MACE (Fig. 3)
suggested that for lesions 20 to 30 mm, additional stenting
was superior to BA, but worse for lesions 40 mm. In the
additional stenting group, a lower MACE rate (16.0% vs.
20.3%, p  NS) and a larger MLD at follow-up (1.64 vs.
1.50 mm) were observed for lesions 26 mm, as compared
with lesions 26 mm. Furthermore, the TVR rate was
significantly lower in those with stents 32 mm (13.1% vs.
23.8%; p  0.13), and use of multiple stents was associated
with an almost doubling of the need for TVR (29.6% vs.
16.7%; p  0.17), as previously reported (23,24).
Potential impact of new developments. Platelet glyco-
protein IIb/IIIa antagonists have been shown to signifi-
cantly improve the clinical outcome one year after stenting
in complex lesions (25). At the time this trial was com-
menced, these data were not available, which may explain
the infrequent use of these agents, which seem justified in
percutaneous coronary intervention of long lesions, and may
have improved the outcome in the stent group. Perhaps of
greater interest are developing measures to reduce intimal
hyperplasia—specifically, exciting reports of virtual elimina-
tion of restenosis by a sirolimus-eluting stent, first in a
registry (26) and, more recently, in a randomized trial (27).
Evaluation of this technology in long lesions seems manda-
tory and will be welcomed by all practitioners, who are
accustomed to the safety of elective stenting and would be
reluctant to return to a strategy of BA (provisional stenting)
without compelling evidence. No such evidence is provided
in this trial.
Study limitations. Randomization to systematic stenting
without an optimal BA result might have added important
data to the trial and needs to be addressed in future studies.
Lack of adjunctive IVUS guidance has been discussed, but
because this is not routine in most clinics, the trial is
representative of clinical practice.
Conclusions. A strategy of provisional stenting in long
lesions led to bail-out stenting in one-third of the patients,
at the cost of a greater than threefold increase in peri-
procedural MI. Additional stenting improved early MLD
and lowered angiographic restenosis, but without improving
nine-month MACE-free survival. These results must be
weighed against the potential benefit of systematic stenting,
which would reduce the risk of bail-out, taking into account
the impending availability of drug-eluting stents, which may
reduce or eliminate restenosis.
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